Cargando…
Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
The function of the immune system in cancer initiation and progression has been widely examined. Notably, immunotherapy has become a promising approach for cancer treatment. CD47, a member of the immunoglobulin superfamily, plays an important role in the immune regulation of cancer by binding to SIR...
Autores principales: | Zhang, Jin, Jin, Shenhe, Guo, Xiaojun, Qian, Wenbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6259379/ https://www.ncbi.nlm.nih.gov/pubmed/30226089 http://dx.doi.org/10.1177/0300060518799612 |
Ejemplares similares
-
Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023) -
Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018) -
Blocking CD47-SIRPα Signal Axis as Promising Immunotherapy in Ovarian
Cancer
por: Luo, Xukai, et al.
Publicado: (2023) -
Glioblastoma Immunotherapy Targeting the Innate Immune Checkpoint CD47-SIRPα Axis
por: Hu, Jinyang, et al.
Publicado: (2020) -
Glutaminyl cyclase is an enzymatic modifier of the CD47- SIRPα axis and target for cancer immunotherapy
por: Logtenberg, Meike E. W., et al.
Publicado: (2019)